Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...
Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...
The report didn’t specify the valuation that FuriosaAI is expected to receive. The company was worth $735 million as of July, ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Zacks.com on MSN
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...
Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...
HOUSTON, TX, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- A Leader in the Midstream Oil & Gas Sector, ...
The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...
Creasing matrix and profile rubbers specialist C&T Matrix will relocate its manufacturing operations this year to a new facility in Poole, Dorset.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results